{"id":542091,"date":"2021-05-06T22:34:01","date_gmt":"2021-05-06T22:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=542091"},"modified":"2021-05-06T22:34:01","modified_gmt":"2021-05-06T22:34:01","slug":"actinic-keratosis-ak-market-size-and-share-trends-epidemiology-and-market-forecast-2030-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/actinic-keratosis-ak-market-size-and-share-trends-epidemiology-and-market-forecast-2030-by-delveinsight_542091.html","title":{"rendered":"Actinic Keratosis (AK) Market Size and Share, Trends, Epidemiology and Market Forecast 2030 by DelveInsight"},"content":{"rendered":"
\"Actinic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u201d Actinic Keratosis (AK) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Actinic Keratosis (AK), historical and forecasted epidemiology as well as the Actinic Keratosis (AK) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

DelveInsight has launched a new report on “Actinic Keratosis (AK) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>.<\/p>\n

DelveInsight’s ” Actinic Keratosis (AK) – Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>″ report delivers an in-depth understanding of the Actinic Keratosis (AK), historical and forecasted epidemiology as well as the Actinic Keratosis (AK) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

1. As per the estimation by DelveInsight’s analysts, the United States had the highest prevalence of Actinic Keratosis with approximately 66 million prevalent population in 2020.<\/p>\n

2. Among the EU5 countries, Germany had the highest prevalent population with approximately 8 million cases followed by the United Kingdom with a prevalent population of approximately 5 million in 2020. On the other hand, Japan has the lowest prevalent population with approximately 7 lakh cases in 2020.<\/p>\n

Key benefits of the report:<\/strong><\/p>\n

1. Actinic Keratosis (AK) market report covers a descriptive overview and comprehensive insight of the Actinic Keratosis (AK) epidemiology and Actinic Keratosis (AK) market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

2. Actinic Keratosis (AK) market report provides insights on the current and emerging therapies.<\/p>\n

3. Actinic Keratosis (AK) market report provides a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

4. Actinic Keratosis (AK) market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Actinic Keratosis (AK) market.<\/p>\n

Request for sample pages: https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market<\/span><\/a><\/strong><\/p>\n

“Males are most commonly affected in case of Actinic Keratosis (AK).”<\/strong><\/p>\n

Actinic Keratosis (AK): Overview<\/strong><\/p>\n

An actinic keratosis is a rough, scaly patch on the skin that develops from years of sun exposure. It’s often found on the face, lips, ears, forearms, scalp, neck or back of the hands.<\/p>\n

Also known as a solar keratosis, an actinic keratosis grows slowly and usually first appears in people over 40. You can reduce your risk of this skin condition by minimizing your sun exposure and protecting your skin from ultraviolet (UV) rays.<\/p>\n

Left untreated, the risk of actinic keratosis turning into a type of skin cancer called squamous cell carcinoma is about 5% to 10%.<\/p>\n

The key players involved in Actinic Keratosis (AK) market are:<\/a><\/strong><\/p>\n

    \n
  1. \n

    Vidac Pharma,<\/p>\n<\/li>\n

  2. \n

    DFB Soria<\/p>\n<\/li>\n<\/ol>\n

    The launch of the emerging therapies is expected to significantly impact the Actinic Keratosis (AK) treatment scenario in the upcoming years:-<\/strong><\/p>\n

    Drugs covered<\/strong><\/p>\n

      \n
    1. \n

      VDA-1102 <\/p>\n<\/li>\n

    2. \n

      SOR 007 <\/p>\n<\/li>\n<\/ol>\n

      Request a free sample report @https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market<\/span><\/a><\/strong><\/p>\n

      Table of Contents<\/strong><\/p>\n

      1. Report Introduction<\/p>\n

      2. Executive Summary<\/p>\n

      3. SWOT analysis<\/p>\n

      4. Actinic Keratosis (AK) Patient Share (%) Overview at a Glance<\/p>\n

      5. Actinic Keratosis (AK) Market Overview at a Glance<\/p>\n

      6. Actinic Keratosis (AK) Disease Background and Overview<\/p>\n

      7. Actinic Keratosis (AK) Epidemiology and Patient Population<\/p>\n

      8. Country-Specific Patient Population of Actinic Keratosis (AK)<\/p>\n

      9. Actinic Keratosis (AK) Current Treatment and Medical Practices<\/p>\n

      10. Unmet Needs<\/p>\n

      11. Actinic Keratosis (AK) Emerging Therapies<\/p>\n

      12. Actinic Keratosis (AK) Market Outlook<\/p>\n

      13. Country-Wise Actinic Keratosis (AK) Market Analysis (2017–2030)<\/p>\n

      14. Market Access and Reimbursement of Therapies<\/p>\n

      15. Market drivers<\/p>\n

      16. Market barriers<\/p>\n

      17. Appendix<\/p>\n

      18. Actinic Keratosis (AK) Report Methodology<\/p>\n

      19. DelveInsight Capabilities<\/p>\n

      20. Disclaimer<\/p>\n

      21. About DelveInsight<\/p>\n

      Related Reports:<\/strong><\/p>\n

      Actinic Keratosis – Pipeline Insights, 2021<\/strong><\/p>\n

      “Actinic Keratosis (AK) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Actinic Keratosis (AK) market. A detailed picture of the Actinic Keratosis (AK) pipeline landscape is provided, which includes the disease overview and Actinic Keratosis (AK) treatment guidelines.<\/p>\n

      Actinic Keratosis – Epidemiology Forecast to 2030<\/strong><\/p>\n

      DelveInsight’s ‘Actinic Keratosis (AK) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Actinic Keratosis (AK) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n

      Actinic Keratosis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020<\/strong><\/p>\n

      “Actinic Keratosis – Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020” report by DelveInsight offers comprehensive insights on marketed and Phase III products for Actinic Keratosis.The marketed products information covers their product details, patents (US & EU), historical and forecasted sales till 2023.<\/p>\n

      Media Contact<\/span>
      Company Name:<\/strong>       DelveInsight Business Research LLP<\/a>
      Contact Person:<\/strong> Kritika Rehani
      Email:<\/strong>       Send Email<\/a>
      Phone:<\/strong> 9193216187
      Address:<\/strong>304 S. Jones Blvd #2432
      City:<\/strong> Las Vegas
      State:<\/strong> Nevada
      Country:<\/strong> United States
      Website:<\/strong>       https:\/\/www.delveinsight.com\/<\/a><\/p>\n

      <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

      DelveInsight Business Research LLP DelveInsight\u2019s \u201d Actinic Keratosis (AK) \u2013 Market Insights, Epidemiology, and Market Forecast-2030\u2033 report delivers an in-depth understanding of the Actinic Keratosis (AK), historical and forecasted epidemiology as well as the Actinic Keratosis (AK) market trends in … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-542091","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=542091"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/542091\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=542091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=542091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=542091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}